AA-A225

N/A

Report date: 2025/11/14 09:32:33

Base Information

Drug NameAA-A225

Drug Alias Nameantiangiogenesis program (Actinium Pharmaceuticals)antiangiogenesis mAb coupled with Ac-225AA-A225

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugateRadiation-emitting products > Nuclides > Actinium > 225Ac +[4]

Mechanisms of ActionAngiogenesis inhibitors

TargetsUpdating

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesActinium Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesActinium Pharmaceuticals Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A